Singapore: Japan-based Dainippon Sumitomo Pharma (DSP), has decided to establish an anti-cancer drugs sales company in t...
Singapore: Japanese company, Kyowa Hakko Kirin and Korean firm, Syndax Pharmaceuticals, have entered into a license agre...
Singapore: Cantrixil, a first-in-class experimental chemotherapeutic, developed by Australia/US-based biotech firm Novog...
Singapore: Auspherix, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial d...
Singapore: Australia and Switzerland based Clinuvel Pharmaceuticals' Singapore subsidiary Vallaurix has successfully com...
Singapore: NephroGenex, pharmaceutical company focused on the development of therapeutics to treat kidney disease, has r...
Singapore: European Medicines Agency (EMA) has accepted Eli Lilly and Boehringer Ingelheim's marketing authorisation app...
Singapore: The Japanese Ministry for Health and Welfare has recently given its nod for Novatris' Cosentyx, that treats p...
Singapore: Australia's Medical Research Commercialisation Fund (MRCF) has invested around $1 million in an early stage a...
Tokyo: Researchers from the RIKEN Center for Integrative Medical Sciences have worked with a number of universities and...
Singapore: Sweden-based company NeuroVive Pharmaceutical's Asia arm has signed a collaboration agreement with Sanofi's a...
Singapore: WuXi PharmaTech, a China-based contract research organization (CRO), has obtained a multiyear license to Adme...
Singapore: Asthma treatment market value will grow from approximately USD15.9 billion in 2013, across eight major countr...
Nemus Bioscience Inc. has announced that the pro-drug of tetrahydrocannabinol (THC) in-licensed from the company's resea...
Singapore: Chinese Food and Drug Administration (CFDA) has approved Israel based D-Pharm to conduct clinical development...
Singapore: In a move to accelerate genome sequencing and bring breakthrough in cancer treatment in the country, UK has...
Tokyo's Mochida Pharmaceutical Co. Ltd. has filed for a new drug application (NDA) for MD-0901 with the Japanese Ministr...
Singapore: Sanofi has terminated NaP2b inhibitors development deal with US based Ardelyx, a clinical-stage biopharmaceut...
